Company profile
Grace Therapeutics, Inc.
NASDAQ:GRCEBiotechnology: Pharmaceutical Preparations
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03398005 | phase3 | completed | 2018-01-23 | 2019-07-21 | Grace Therapeutics Inc. | A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1) |
| NCT03361501 | phase3 | completed | 2018-02-01 | 2019-09-24 | Grace Therapeutics Inc. | A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2) |
| NCT01516151 | phase2 | completed | 2011-12-01 | 2013-05-01 | Grace Therapeutics Inc. | Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia |
| NCT05531890 | phase1 | unknown | 2022-09-13 | 2022-11-24 | Grace Therapeutics Inc. | Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects |
| NCT05418348 | phase1 | completed | 2021-08-26 | 2022-02-17 | Grace Therapeutics Inc. | Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects |
FDA applications (0)
No records yet.